Warning Letter — Yangzhou Hongshengding Chemical Co., Ltd.
The FDA issued a Warning Letter to Yangzhou Hongshengding Chemical Co., Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER).
The issuance affects Yangzhou Hongshengding Chemical Co., Ltd. and potentially any downstream pharmaceutical manufacturers or distributors utilizing their chemical products in FDA-regulated drug products.
This action indicates that the facility failed to meet core regulatory requirements during an FDA evaluation. While the specific nature of the violations is not detailed in the available excerpt, a Warning Letter from CDER typically signals significant deviations from cGMP, which may compromise the quality and safety of the chemicals produced. Regulatory professionals should interpret this as a high risk for supply chain disruption.
Quality units should verify that international suppliers adhere to current Good Manufacturing Practice (cGMP). Procurement and regulatory teams should monitor the firm's compliance status, as Warning Letters often precede import alerts or restrictions on product entry into the U.S. market.
FDA Warning Letter issued to: Yangzhou Hongshengding Chemical Co., Ltd.. 06/15/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/yangzhou-hongshengding-chemical-co-ltd-729710-06152026
Open in openFDA / FDA.gov